PUBLISHER: NikkeiBP | PRODUCT CODE: 1219562
PUBLISHER: NikkeiBP | PRODUCT CODE: 1219562
“The Directory of Biotech Startups in Japan 2021-2022” was created for businesses looking for new partners in the biotechnology field. If you are a pharmaceutical company, you are constantly screening startups for new drug candidates. If you are a fund, you are compiling a list of new investments for the next round. This directory is the perfect company database for you. The directory contains information on 395 Japanese biotech startups.
This Directory includes the following Background of establishment, characteristics of the technology, details of patents, R&D projects being worked on, investors (venture capital, etc.), capital policy, management team, etc. In addition, the reporters directly interviewed 207 of the 395 companies and prepared detailed company reports.
Nikkei Biotechnology & Business is a specialized biotechnology media with over 40 years of history in Japan. In cooperation with major universities and prominent venture capitalists throughout Japan, the analyst regularly surveys startups in the biotechnology field. Among them, Nikkei Biotechnology & Business has selected 395 with outstanding technologies and business models. Many startups do not have their own website and disclose less information compared to larger, listed companies. In this respect, “The Directory of Biotech Startups in Japan 2021-2022” is packed with hard-to-find and must-have information for those who desire to invest in biotech startups.
Editors of Nikkei Biotechnology & Business contacted each and every startup introduced in this directory to research their technology, patents, collaborators, shareholders and other information. You can compare the 395 startups in a unified format. Of the 395, the editors conducted interviews with 207 of particular note to analyze their technological features and management strategies, to prepare detailed company reports for the directory. “The Directory of Biotech Startups in Japan 2021-2022” can be used as screening document for pharmaceutical giants and venture funds around the world looking for new business partners.
Nikkei Biotechnology & Business has focused on modalities to create an industry map of the drug discovery startups covered in this directory. First, the products developed by the startups were categorized into 11 tables by the following modalities: "Small molecules" "Peptides" "Antibodies (including antibody-drug conjugates; ADCs)" "Proteins" "Nucleic Acids" "Gene Therapy" "Cell Medicine" "Regenerative Medicine" "Vaccines (including Adjuvants)" "Other modalities" and "Digital (Digital Health and Digital Therapeutics)".